Promising combo takes aim at Hard-to-Treat pancreatic cancer
NCT ID NCT07173387
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests a chemotherapy regimen called NALIRIFOX combined with precise radiation (SBRT) in 42 people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this approach can delay cancer growth and improve survival. Participants receive either early or late radiation after starting chemo, and are followed for at least two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NALIRIFOX chemotherapy (liposomal irinotecan, oxaliplatin, 5-fluorouracil, leucovorin) and Stereotactic Body Radiation Therapy (SBRT)
What this could lead to
If successful, this combination could offer a new treatment option to control locally advanced pancreatic cancer and extend survival without surgery.
What could go wrong
This is a small Phase 2 trial (42 people) with no control group, so results may not be definitive. Chemotherapy and radiation have significant side effects, and the cancer may still progress.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shandong Cancer Hospital and Institute
Jinan, Shandong, 0531, China